Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 5/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL184474 | 0.83 | TSHR (0.58) | HPGDSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2188210 | 0.82 | SMPD1 (0.76) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL29375753 | 0.82 | SMPD1 (0.75) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL1029034 | 0.82 | SMPD1 (0.75) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL9236564 | 0.80 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL4270566 | 0.80 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL11271923 | 0.80 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| Hydrochloric Acid SCHEMBL6586504 | 0.80 | SMPD1 (0.73) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL6584177 | 0.80 | SMPD1 (0.81) | SMPD1HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL20909473 | 0.80 | SMPD1 (0.81) | SMPD1HDAC1HDAC8HDAC6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340522-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| EP-2356103-B1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-9090597-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-8865745-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | TAKEDA GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| CN-103463086-A | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH | 2013-12-25 | — | — | CN | disclosed |
| US-8609848-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| US-8304436-B2 | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| EP-2508520-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2402330-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2148876-B1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2356103-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | Nycomed GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010055083-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| EP-2148876-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | Nycomed GmbH (DE) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008138939-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3A | SMPD1 79/4885HDAC1 144/4885HDAC8 1105/4885 |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE5A | SMPD1 167/4885HDAC1 163/4885HDAC8 289/4885 |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | SMPD1 89/4885HDAC1 214/4885HDAC8 624/4885 |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | SMPD1 118/4885HDAC1 173/4885HDAC8 241/4885 |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | SMPD1 89/4885HDAC1 214/4885HDAC8 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.